

---

2025 Korea-US Collaborative Research Project Call for New Project Applications

---

2025 1st Korea-US

Collaborative Research Project

Call for New Project

Applications

March 18, 2025.

**Korea-US Collaborative Research Fund**

# Table of Contents

<b>I . New Support Plan for 2025</b> .....	1
1. Promotion Direction.....	1
2. Support Contents and Scale for New Projects .....	1
3. Promotion Schedule.....	3
<b>II . Application Requirement and Method</b> .....	6
1. Application Requirement .....	6
2. How to Apply .....	15
<b>III . Selection Evaluation Procedure and Method</b> .....	22
1. Selection Evaluation Procedure .....	22
2. Selection Valuation Method and Criteria .....	24
<b>IV . Managing Future Research Projects</b> .....	25
<b>V . Others</b> .....	33
<b>VI . Contact Information</b> .....	33
[Attachment 1] Acquisition and Management of Research Facilities and Equipment .....	35
[Attachment 2] Mandatory IRB Review under the Bioethics Act .....	37
[Attachment 3] Registration of R&D Information and Evaluation, Reporting, and Disclosure of R&D Results .....	40
[Attachment 4] Criteria for Awarding Additional Points .....	45

# 2025 New Project Support Plan

## 1. Project Implementation Direction

- Promote advanced bio joint research with a focus on excellence by forming consortia between outstanding research groups in Korea and the United States.
- Support designated projects in fields that require global cooperation, based on national advanced bio policy directions, to foster sustainable international joint research in advanced bioscience.
- Without limiting the research stage of technology, concentrate domestic research capabilities and national investment capacity in the advanced bioscience sector.
- In consideration of the unique characteristics of global joint research projects in advanced bioscience, a cross-ministerial project group (Korea-US Collaborative Research Fund) has been established for efficient program management. The office aims to support excellence-based project selection and innovation-driven joint research aligned with actual research demands.

## 2. New Project Support Details and Scale

- ※ Please refer to the Request for Proposal (RFP) for detailed support information.
- ※ The number of selected projects is subject to change based on the evaluation process and review results.

**< 2025 New Project Support Details and Scale >**

RFP Title	Project Type	Support Scale (Year 1)	Support Duration	Eligibility / Project Composition Requirements	Expected Number of Projects
Korea-U.S. Collaborative Research Support	Open Call Type	KRW 2 billion total (KRW 1 billion in Year 1)	Up to 4 years (6 months in Year 1)	- (Eligible Entities) Industry, Academia, Research Institutes, and Medical Institutions Must include a Korean primary R&D project and a U.S. joint R&D project (additional joint R&D participants may be included)	Up to 7
<b>Total</b>					<b>Up to 7</b>

### 3. Project Schedule

- ※ Strictly adhere to **the application deadline (14:00:00)** (No extensions will be granted after the deadline)
- ※ Please refer to the notices on the Korea-US Collaborative Research Project website for information on the presentation evaluation schedule, competition rate, and other evaluation-related details.
- ※ The schedule below is subject to change depending on the progress of the evaluation process.

- **March 18, 2025**                      Project announcements
- **March 26, 2025**                      Start of online project entry (application intake)
- **April 25, 2025, (Research Director) Project application (system 14:00:00 entry) deadline**
- **Apr 25, 2025, (Primary research institution) Electronic certification (or official document submission) deadline 15:00:00**
- April 2025                              Preliminary review of research proposal
- March - May, 2025                      Establishment of evaluation plan and formation of evaluation committee
- May 2025                                Advance notice of evaluation schedule and

competition rate

Document evaluation and announcement of

- May 2025 projects selected for presentation evaluation
- June 2025 Presentation evaluation
- July 2025 Announcement of final selection results
- July 2025 Contract signing and project commencement

**<Before Application>**

- Researchers must read the contents of the **Request for Proposal (RFP)** and **Call Announcement Guide** before applying.
  - Confirm eligibility, funding amount and duration, and project support details.
- **After the application deadline (system entry), it will not be possible to make changes to the research field, research plan content, etc.,** so apply with care.
- **Overseas researcher registration may take more than one week,** so please check and complete registration **in advance.**
- Researchers must comply with Article 64 (Limitation on the number of R&D projects) of the Enforcement Decree of the National R&D Innovation Act.
  - During the **pre-selection stage**, the number of national R&D projects simultaneously conducted by the research director will be checked.
  - If the number exceeds the allowable limit, **the selected project may be disqualified.**

※ Before applying, the research director must verify their current number of concurrently conducted national R&D projects to determine eligibility for submission.

○ Researchers **must use NTIS (www.ntis.go.kr) to check for similarities** between the proposed research plan and existing national R&D projects (including those from other ministries) **prior to application.**

\* How to check for similar projects:

- Visit [www.ntis.go.kr](http://www.ntis.go.kr) > Log in > Project Participation > Similar Projects > Similarity Review

### 1. Application Requirements

#### 1) Eligibility of R&D Institutions and Research Directors

##### q Eligibility of R&D Institutions

○ An R&D institution must satisfy the requirements set forth in Article 2, Paragraph 3 of the National Research and Development Innovation Act.

**[National Research and Development Innovation Act, Article 2 (Definitions), Paragraph 3]**

3. "Research and Development Institution" refers to an institution or organization that conducts national R&D projects and falls under any of the following categories:

- a. Research institutes established and operated directly by the national or local government
- b. Universities as defined under Article 2 of the Higher Education Act
- c. Government-funded research institutes under Article 2 of the Act on the Establishment, Operation, and Fostering of Government-funded Research Institutes, etc.
- d. Government-funded research institutes in science and technology under Article 2 of the Act on the Establishment, Operation, and Fostering of Government-funded Research Institutes in the Field of Science and Technology
- e. Local government-funded research institutes under Article 2 of the Act on the Establishment and Operation of Local Government-funded Research Institutes
- f. Specific research institutes under Article 2 of the Specific Research Institutes Support Act
- g. Companies under Article 169 of the Commercial Act
- h. Other institutions or organizations designated by Presidential Decree

##### q Eligibility of Research Directors

○ The research director must be a researcher affiliated with an R&D institution as defined in Article 2, Paragraph 3 of the above Act.

○ The research director must be employed as research personnel at the

applying institution.

※ If the research director is expected to retire during the project period and therefore lose eligibility, please consult in advance before applying.

Failure to meet the eligibility requirements of the institution or research director may result in disqualification, so applicants are strongly advised to verify eligibility prior to submission.

## 2) Application Restrictions

### q Restrictions on Application and Participation

○ Researchers under participation restriction in national R&D projects as of the application deadline are not eligible to apply.

- According to Article 32 of the National Research and Development Innovation Act, individuals currently restricted from participation are ineligible, but may apply if their restriction period ends before the deadline.

○ Researchers who exceed the limit on concurrent national R&D project participation are ineligible.

- As per Article 64 of the Enforcement Decree, a researcher may participate in up to 5 R&D projects concurrently, and serve as research director on up to 3 projects.

- In the case of “Joint Institution Type” projects where a foreign institution bears R&D costs, the limit is expanded to 6 concurrent projects, with 4 allowed as research director. (Refer to Article 64(2) of the Enforcement Decree of the Act)

< Concurrent Project Participation Limits (3 Research Director / 5 Projects Rule) >

Role	Research Director	Other Researchers
Primary R&D Project (Institution)	Research Director (Included in research director limit 3)	Participating Researcher (Included in project limit 5)
Joint R&D Project (Institution)	Participating Researcher (Included in project limit 5)	

-

\* Subcontracted research directors and participating researchers in subcontracted projects are not subject to these restrictions.

\* If a currently ongoing project ends within 6 months of the application deadline, it is not counted toward the participation limit.

- A preliminary screening will be conducted after submission to check participation limits. So the researchers must check their current number of concurrent national R&D projects in advance to confirm eligibility.
- If a research director exceeds the allowed limit, the project may be disqualified even after selection.

○ (Participation rate): The sum of participation rates across all national R&D projects in which a researcher is involved must not exceed 100%.

○ (Application limit): Each researcher may submit only one application as RD of a primary or collaborating institution. (This applies equally to U.S.-based researchers.)

### **3) Project Composition Requirements**

#### **q R&D Project Structure Requirements**

○ The proposal must include detailed descriptions of the research activities to be conducted by the overseas institution (technical collaboration, role allocation, and budget utilization plans).

- A joint research team consisting of Korean and U.S. researchers should apply together. Formation of multidisciplinary or interdisciplinary teams\* is strongly encouraged.

\* Research groups that combine multiple academic fields and disciplines to promote originality and excellence in global joint research.

- **Documentation confirming the overseas research director's intent to**

participate (Letter of Intent (LOI) or Letter of Support, etc.) must be submitted.

- Detailed information on cash or in-kind contributions to be provided by the overseas institution must be included.

※ Project budgets may be adjusted during evaluation, and the research period, scope, and funding may change depending on budget availability, policy shifts, or legal/regulatory revisions.

○ As this is a joint research project led by a domestic institution, prior coordination between the domestic (primary) and overseas institutions must take place.

\* Eligible overseas institutions include hospitals, research institutes, and universities headquartered and located in the United States (Corporations are not eligible).

\* Overseas collaborating researchers must be affiliated with U.S.-based institutions. Researchers temporarily dispatched from Korea, such as sabbatical, visiting scholars, are not eligible even if they are affiliated with a U.S. institution at the time of application.

- If the overseas partner withdraws after project initiation, the domestic primary institution is held accountable for any resulting inability to proceed.

- Participation should follow the “Joint Institution Type” model in international joint research.

\* This requires a formal agreement between the Administrative Office and the overseas institution, and the foreign institution must contribute R&D costs (cash or in-kind). Refer to the International Joint R&D Manual for details.

\* Standard agreement templates will be made available on the program website ([www.kucrf.org](http://www.kucrf.org)), and contracts will be signed with selected overseas institutions after project selection. The Administrative Office will also assist with agreements between institutions regarding ownership and attribution of R&D results.

○ A single R&D institution may not participate in duplicate roles within one project.

- The same R&D institution cannot participate simultaneously in a single project as a primary, collaborating, or subcontracted organization.

※ R&D institutions are identified based on corporate registration number. (Even if business registration numbers are different, duplicate participation is not permitted if the corporate registration number is the same.)

#### **4) Other Important Notes**

##### **q Quantitative Specification of Expected Research Outcomes**

○ When submitting the research plan, researchers must quantitatively specify the expected research outputs (publication of papers, patent applications/registrations, etc.) by the end of each research phase and the overall project duration, using the prescribed format.

○ If the project fails to meet the performance targets set during the application, consequences such as recovery of R&D funds or restrictions on future participation may apply. Therefore, it is crucial to present realistic and achievable performance targets.

##### **q Duplication Review**

○ Applicants must check for overlap with national R&D projects that are ongoing or have been previously funded, using the National Science

& Technology Information Service (NTIS) at [www.ntis.go.kr](http://www.ntis.go.kr). The primary research director may be required to explain any potential overlap.

- If the project is flagged as potentially overlapping in NTIS, the project evaluation committee will assess the duplication during the selection evaluation.

- Researchers must verify in advance the similarity between their proposed research and existing national R&D projects (including those from other ministries).

※ How to search for similar assignments: [www.ntis.go.kr](http://www.ntis.go.kr) → Log in → Project Participation → Similar Projects → Similarity Review

#### q **Procurement and Management of Research Facilities and Equipment**

○ If you plan to purchase research equipment/facilities valued between KRW 30 million and KRW 100 million,

- A “Research Equipment Budget Review Request Form” must be completed and attached when submitting the research plan.

- Equipment and facilities within this price range will be reviewed by the Project Evaluation Committee, while those over KRW 100 million will be reviewed by the National Research Facility and Equipment Review Committee (under the Ministry of Science and ICT). (See Attachment 1)

○ The purchase of equipment/facilities exceeding USD 30,000 by overseas institutions is not allowed in principle.

- However, if such purchase is essential for conducting research, the

overseas institution must obtain prior approval from the Administrative Office.

q **Mandatory IRB Review under the Bioethics and Safety Act**

○ In accordance with the Bioethics and Safety Act, researchers conducting human subject research or research involving human-derived materials must obtain IRB (Institutional Review Board) approval from their institution before the agreement is signed for the given year. (See Attachment 2)

q **Registration of R&D Information and Evaluation, Report and Disclosure of R&D Results**

○ In accordance with relevant laws, research outcomes must be registered or deposited with the designated sector-specific management agencies responsible for R&D results. (See Attachment 3)

q **Submission of Proof of Postdoctoral Employment**

○ If selected as a new project and if any participating researcher qualifies as a postdoctoral researcher under Article 2, Subparagraph 3 of the Enforcement Decree of the Act on Promotion of Basic Research and Support for Technology Development, the employment contract or equivalent proof of employment must be submitted with the finalized research plan for the agreement.

## **2. How to Apply**


### **1) Online Entry Instructions**

## q How to Access the Entry System

o The research director must log in to the Integrated R&D Information System (IRIS, <https://www.iris.go.kr>) to complete online input, upload the research proposal, and request confirmation/approval from the primary research institution.

## q Application Procedure

o The research director logs in to IRIS (<https://www.iris.go.kr>), fills out the required information online, uploads the research plan and other documents, then the primary research institution confirms and approves the application.



※ Before applying, confirm with your institution's research administration officer whether approval from the primary institution is possible.

▶ There are required pre-submission actions to apply through IRIS. Please prepare in advance to avoid submission issues.

※ For details, refer to the following: [Attachment] Required Pre-Submission Actions (KISTEP IRIS Operations Office), IRIS Membership (Researcher Conversion) and Information Entry Manual

① **(Researchers)** ① Register for IRIS membership, ② Within IRIS, access NRI (National Researcher Information System) and agree to researcher conversion (to receive National Researcher ID), ③ In NRI, register academic background/career\* and major research achievements\*\*.

\* Career info must include department (affiliated organization)

\*\* Include completed projects within the past 5 years, ongoing/applied projects list

※ Steps ① and ② are mandatory for all participating researchers including the research director (except student researchers from institutions with centralized student labor management)

Step ③ is required only for the research director

② **(R&D Institutions)** Complete IRIS institution registration, assign an institutional representative, and register the legal representative of the institution.

※ The institutional representative and legal representative must also register for IRIS and agree to researcher conversion (receive National Researcher ID). If the legal representative is not registered, the researcher will be unable to complete the project submission. This must be completed before the application period starts.

▶ IRIS Contact: IRIS Call Center 1877-2041 or use the Help section on the IRIS website

q

<Precautions>

- When applying for multiple R&D projects as part of a consortium, make sure that each sub-project is fully submitted, and confirm that the primary research project shows a “submission completed” status.  
(If the primary research project is not marked as submitted, the entire application is not considered complete.)
- After completing up to Step 3, the research director must request confirmation and approval from the primary research institution.  
(If the institution’s electronic certification or official project submission letter is not submitted, the project will not be processed.)  
※ For primary research projects, confirmation and approval must be done by the primary research institution.
- During the last two days before the deadline, the IRIS system may experience slowdowns or access issues due to high traffic. Please allow ample time for submission.
- Overseas researcher registration may take more than one week, so please complete registration in advance.

## 2) Calculation of R&D Expenses

### q Basis for Calculating R&D Expenses

- Applicants must calculate the appropriate R&D expenses required to perform the proposed research, taking into account the amount of government funding and in accordance with the “Standards for the Use of R&D Expenses for National R&D Projects” (Ministry of Science and ICT Notice No. 2025-6, issued on 2025.2.19).

※ If the proposal does not comply with the RFP or relevant regulations/guidelines, the final support amount may be adjusted.

※ Guidelines for subcontract auditing fees will be provided separately after project selection.

○ Indirect costs should be calculated in accordance with Annex 6 of the above standards and are included in the total R&D budget.

**q Participating Company Contributions (Calculated Per Project)**

※ If the RFP specifies different standards, the RFP takes precedence

※ Contributions must be paid at least 3 months before the end of the current year’s project period. Failure to meet this deadline may result in suspension or sanctions following a special review.

○ Standards for Participating Company Contributions

Item	Large Enterprises	Medium-sized Enterprises	Small Enterprises
Required share of total R&D expenses	≥ 50% of total R&D expenses	≥ 30% of total R&D expenses	≥ 25% of total R&D expenses
Required cash portion	≥ 15% of the contribution amount	≥ 13% of the contribution amount	≥ 10% of the contribution amount
Allowable in-kind contributions from Required share of total R&D expenses	a. Salary of affiliated researchers not funded by institutional overhead b. Costs of research facilities and equipment c. Technology acquisition and research material costs		

○ For medium- and small-sized enterprises, if they hire at least one young employee (aged 18-34) while conducting the R&D project, the

equivalent salary amount can be substituted as in-kind contribution in place of the required cash portion.

- If the executed salary amount is less than the reduced cash obligation, the difference must be returned at year-end reconciliation.

\* This applies when total government support for the project exceeds KRW 500 million during the entire research period.

(Example: KRW 500 million project & 2 employees hired → 1 employee's salary credited, KRW 1 billion project & 3 employees hired → 2 employees' salaries credited)

### 3) Preparation of the Research Plan

○ The Research Plan and Attachment Forms must be downloaded and completed from the IRIS website under the announcement titled: 2025 Korea-US Collaborative Research Project Call for New Project Applications.

\* [www.iris.go.kr](http://www.iris.go.kr) → [Project Announcements] → 2025 Korea-US Collaborative Research Project Call for New Project Applications → Download attached files

\* No printed/hard copy submission is required

○ Both the main research plan and attached documents will be reviewed during both the written and presentation evaluations.

#### < 2025 Project Support Details and Scale >

RFP Title	Project Type	Scale (Year 1)	Support Duration	Main Research Plan (Body)	Attachments
Korea-U.S. Collaborative	Open Call	KRW 2 billion/year	Up to 4 years(6 months for Year 1)	1) Master plan up to 20 pages 2) Each primary/joint plan up to 10 pages per institution	Use prescribed templates

Research Support					
------------------	--	--	--	--	--

○

#### 4) Submission Deadlines

Category	Details
Announcement Period	March 18 (Tue), 2025 - April 25 (Fri), 2025, 14:00
Research Director Online Application Period	March 26 (Wed), 2025 - April 25 (Fri), 2025, 14:00
Institution Review Deadline	By April 25 (Fri), 2025, 15:00
Application Process	Researcher application ▷ Institution approval ▷ Submission complete

q

- ※ The research director must submit the research plan and request institutional review and approval by the deadline. The application is only finalized when it is approved by the head of the primary research institution. **(If not approved by the deadline, the application will be excluded from consideration.)**
- ※ **Strictly adhere to the deadline (April 25, 14:00 KST) – no extensions will be granted.**
- ※ Information on presentation evaluations, competition rates, etc., will be posted in the Notices section of the **Korea-US Collaborative Research Project website (www.kucrf.org)**.
- ※ Late or incomplete submissions will not be accepted under any circumstances. As the system may be slow or inaccessible near the deadline (within 2 days prior), applicants are advised to complete submissions well in advance.



# Selection Evaluation Process and Methodology

## 1. Selection Evaluation Process


### < Selection Evaluation Procedure >



Review the following: project composition requirements, qualifications of R&D institutions and research directors participation restrictions, company cost-sharing obligations, required attachments, etc.

After the review, determine the list of projects subject to the first written evaluation

Projects scoring 30 points or below in the "Differentiation" category will be referred to the evaluation subcommittee for review




Assess RFP alignment and evaluation criteria

Projects scoring below 70 out of 100 are disqualified

Select projects to proceed to the 2nd evaluation round

※ Approximately 4 times the number of final selections will be shortlisted




(Domestic) Presentation evaluation → scoring & feedback → final ranking determination

※ NTIS search results will be used to re-evaluate project differentiation

(Projects scoring 30 points or below in differentiation and deemed duplicates will be excluded)

(US) Written evaluation → ranking & feedback

\* Based on NIH-style review



## **2. Evaluation Methodology and Criteria**

### **q Evaluation Methodology**

○ Evaluation will be based on a presentation by the primary research director, and will follow this sequence:

- Written Evaluation  $\Rightarrow$  Presentation Evaluation  $\Rightarrow$  Comprehensive Review

-

### **q Evaluation Criteria**

○ Key evaluation items will be based on the Request for Proposal (RFP).

○ Bonus and Penalty Points

- Bonus or penalty points are applied per project based on eligibility and supporting evidence. Application of points will follow the criteria and procedures defined in Attachment 4.

※ Applicants requesting bonus points must fill out the Bonus Point Application Form (included in the attachments), and submit it together with supporting documents. If necessary, additional documentation may be requested prior to the presentation evaluation.

**1) Submission of Annual, Phase, and Final Reports**

○ The R&D institution and research director must submit the following reports to the Administrative Office by the deadlines specified below:

- Annual Report: On the final day of each annual research period
- Phase Report: On the date each phase of the project is completed\*

\* Refers to the date by which the phase report is fully completed, including any necessary revisions following phase evaluation. Reports must be submitted by the date separately designated by the Administrative Office for the phase evaluation.

- Final Report: Within 60 days after the end date of the R&D project agreement

**2) Phase Evaluation**

○ A performance grade will be assigned based on the outcome of the phase evaluation.

- If the project implementation is deemed inadequate and performance falls significantly short of the proposed plan, a grade of “poor” may be assigned and the budget may be adjusted.

○ Papers and patents will be recognized as official research outcomes only if they are clearly linked to the supported project and explicitly acknowledge funding from the Korea-US Collaborative Research Project, organized by the Ministry of Science and ICT and the Ministry

of Health and Welfare.

○ Korea-US Collaborative Research Project may conduct on-site inspections when necessary. In such cases, the R&D institution and the research director must actively cooperate.

### **3) Final Evaluation**

○ A final performance grade will be assigned through the final evaluation process.

- If project implementation is inadequate and the performance falls significantly below expectations, the project may receive a “poor” rating and may be subject to sanctions.

○ Papers and patents will be recognized as official project outputs only if they are clearly related to the project and specify that the work was supported by the Korea-US Collaborative Research Project (Ministry of Science and ICT and Ministry of Health and Welfare).

### **4) Special Evaluation**

○ In the following cases, a special evaluation may be conducted, and based on the results, the project objectives, research director, or the project itself may be modified or terminated:

- If research misconduct related to national R&D occurs during project execution.

- If the research director becomes restricted from participation in national R&D activities.
  - If changes in the R&D environment make continued execution of the project unnecessary.
  - If the request for modification or termination is approved by the R&D institution or research director.
  - If the researcher or R&D institution fails to meet obligations under applicable laws or the funding agreement, or if continued execution of the project is deemed impossible.
  - Other cases where project modification or termination is deemed necessary under a Presidential Decree.
- The R&D institution or research director may also request a change in project objectives or research director, or request project termination in the following cases:
- If the R&D environment has changed, or if project objectives have been fully achieved early, making continued execution unnecessary.
  - If continued execution of the project is judged to be no longer feasible.

## **5) Manage and Report on Research Outcomes**

### **q Ownership and Management of R&D Outcomes**

- In principle, R&D outcomes shall be owned by the R&D institution that carried out the project and inherited the rights from the researcher.

○ Depending on the type of outcome and the type and proportion of participation, outcomes may be owned by individual researchers or jointly owned by multiple R&D institutions.

- If multiple R&D institutions individually generate outcomes, the institution that generated each outcome shall own it.

- If multiple institutions jointly generate outcomes, the ownership ratio shall be determined based on contribution. However, if the involved institutions agree on ownership ratios or implementation rights through separate consultation, that agreement shall prevail.

- If a subcontracted R&D institution generates an outcome, it shall be owned by the primary research institution.

#### q **Reporting on Utilization of R&D Outcomes**

○ The R&D institution and the research director shall submit a Report on the Utilization of R&D Outcomes to the relevant central administrative agency, upon request, after the completion of the project.

#### q **Follow-up Survey to Promote Utilization of R&D Outcomes**

○ In accordance with Article 17(5) of the National Research and Development Innovation Act, the head of a central administrative agency may require the head of the R&D institution to submit a Performance Utilization Report annually by the end of February for five years, starting the year after the project ends.

#### q **Indicating Project Details and Registering Outcome Information**

○ When publishing research outcomes, it must be clearly stated that

the results were achieved with support from the Korea-US Collaborative Research Project.

- For media announcements, prior consultation with the Administrative Office is mandatory.
- For domestic and international academic publications or patent applications, acknowledgment must follow the formats below.

**< Academic Paper >**

- \* Korean: "본 연구는 과학기술정보통신부 및 보건복지부의 재원으로 보스턴 코리아 공동연구지원사업에 의하여 이루어진 것임 (과제번호: RS-2025-00000000)."
  - \* English: "This research was supported by a grant of the Korea-US Collaborative Research Fund (KUCRF), funded by the Ministry of Science and ICT and Ministry of Health & Welfare, Republic of Korea (grant number: RS-2025-00000000)"
- ※ Use the RS- prefixed project number assigned to your project.

**< Patent >**

- \* When to indicate project source: When preparing or amending the patent application
  - \* How to indicate project source
    - 【Assignment Unique Number】: NTIS project unique number
    - 【Project Number】: IRIS project number (starts with RS-)
    - 【Ministry Name】: Ministry of Science and ICT, Ministry of Health and Welfare
    - 【Managing Agency】: National Research Foundation (NRF), Korea Health Industry Development Institute (KHIDI)
    - 【Project Name】: Korea-US Collaborative Research Project
    - 【Project Title】: Title of the R&D project that produced the patent
    - 【Contribution Rate】: If supported by multiple projects, express as fractions (e.g., ○/□) that total 1
    - 【Primary Institution】: Name of the institution that conducted the relevant R&D project
    - 【Study Period】: Period as stated in the project agreement.
- ※ Use the RS- prefixed project number assigned to your project.

○ The Research director must ensure that all outcomes (e.g.,

publications, patents) are registered in the Integrated Research Support System ([www.iris.go.kr](http://www.iris.go.kr)) within one month of occurrence to avoid omissions, both during and after the project.

#### q **Registration of R&D Information and Evaluation, Report and Disclosure of R&D Results**

○ In accordance with the Notification on Designation of Institutions for Research Outcomes Management and Distribution, R&D outcomes must be registered or deposited with the designated institution using the procedures specified by the management agency. (See Attachment 3 for details)

#### q **Guidelines on Technology Fees**

○ Collection and Reporting of Technology Fees

- Institutions owning R&D outcomes may enter into license agreements specifying the scope of implementation rights, technology fees amounts, and payment terms.

- Such institutions must collect technology fees and report the results of technology fees collection to the appropriate authority.

○ Government Technology Fees Payment Obligations and Criteria

- SMEs, mid-sized enterprises, and public enterprises that collect royalties or directly implement R&D outcomes must pay a portion of the royalties or resulting revenue to the government.

○ In accordance with Article 18, Paragraph 2 of the National Research and Development Innovation Act, if technology fees are collected or revenue is generated from R&D outcomes, the institution obligated to pay such technology fees must do so by the

earlier of the following two dates: five years from the year following the year in which the technology fees were first collected or the R&D outcome revenue was first generated, or seven years from the date the project was completed.

Organizations obligated to pay technology fees	If technology fees are collected from third parties	If revenue is generated through direct implementation	Maximum payment
Large Enterprises/Public Enterprises	20% of collected technology fees	R&D revenue x Contribution ratio x 20%	40% of government funding
Mid-sized Enterprises	10% of collected technology fees	R&D revenue x Contribution ratio x 10%	20% of government funding
Small Enterprises	5% of collected technology fees	R&D revenue x Contribution ratio x 5%	10% of government funding

## V

### Others

○ The selection and evaluation process may be adjusted depending on the situation.

- Presentation evaluations may be replaced with online (non-face-to-face) evaluations, if necessary. In such cases, separate notices or individual guidance will be provided.

○ Any items not specified in this announcement shall be governed by the National Research and Development Innovation Act, its Enforcement Decree and Enforcement Rules, the Health and Medical Technology Promotion Act, and related sub-regulations.

\* Details may change in accordance with the enactment or revision of relevant laws and regulations.

## VI

### Contact Information

○ Official Websites

- Ministry: Ministry of Science and ICT ([www.msit.go.kr](http://www.msit.go.kr)),

Ministry of Health and Welfare ([www.mohw.go.kr](http://www.mohw.go.kr))

- Organization : National Research Foundation of Korea ([www.nrf.re.kr](http://www.nrf.re.kr))

Korea Health Industry Development Institute ([www.htdream.kr](http://www.htdream.kr)), etc.

- Project Announcement: Integrated Research Support System ([www.iris.go.kr](http://www.iris.go.kr)),

Korea-US Collaborative Research Project website

(www.kucrf.org), etc.

- Managing Organization: Korea-US Collaborative Research Project  
(www.kucrf.org)

○ Person in Charge

- Request for Proposal (RFP) announcements, postings, and evaluations

RFP	Type	Contact & Evaluation Details
		Phone / Email
U.S.-Korea Collaborative Research Support	Open Call	Korea-US Collaborative Research Project 02-2072-4354/4353/4355 kucrf@snuh.org

- For system input and proposal submission : Integrated Research Support System (1877-2041)

※ IRIS Call Center Hours : 09:00 - 18:00

## **Acquisition and Management of Research Facilities and Equipment**

(Refer to the Standard Guidelines for the Management of National R&D Facilities and Equipment)

○ Deliberation for the acquisition of research facilities/equipment (KRW 30 million - under KRW 100 million)

- At the time of submitting the research and development (R&D) plan, a “Research Equipment Budget Review Request Form (for items valued between KRW 30 million and under KRW 100 million)” must be completed and attached.

○ For research facilities/equipment valued at KRW 100 million or more, deliberation must be conducted by the National Research Facility and Equipment Review Committee (supervised by the Ministry of Science and ICT) - further instructions will be provided to selected projects.

※ After project selection: For facilities/equipment exceeding KRW 100 million in the following fiscal year, the main deliberation by the above Committee must be completed. (Usually held around May each year.)

○ If there are changes related to the acquisition of research facilities and equipment (changes in budget, cancellation of purchase, etc.), the head of the R&D institution must report and receive approval through the primary research institution from both the Administrative Office and relevant implementing agencies.

○ The head of the R&D institution must register any equipment worth KRW 30 million or more (or less, if expected to be shared) within 30 days of acquisition in the ZEUS R&D Facility and Equipment Information System (<http://www.zeus.go.kr>), and confirm whether a “National Research Facility and Equipment Registration Certificate” has been issued.

- At the time of final expense settlement and final report submission, the Registration Certificate must be obtained and submitted.

## Mandatory IRB review under the Bioethics Act

(Refer to the Bioethics and Safety Act)

### ▶ Institutional Review Board (IRB)

- A self-regulating and independent ethics committee established in institutions conducting research that involves human subjects, human-derived materials, embryos, or genetic material. The IRB conducts ethical and scientific reviews of research protocols, oversees research implementation, and ensures the protection of both researchers and research subjects.

### ▶ Bioethics and Safety Act (Effective: September 12, 2020)

- Institutions where human subjects research or human-derived materials research is conducted (e.g., universities, research institutes, hospitals) must establish an IRB to review the ethical and scientific validity of submitted research proposals.

※ Fines is up to KRW 5 million for not establishing an IRB and up to KRW 2 million for not registering the IRB.

- ▶ All research subject to the Bioethics Act must undergo IRB review by the implementing institution.

## q Key Provisions of the Bioethics Act

○ **(Purpose)** To prevent violations of human dignity or harm to the human body in research involving human participants, embryos, or genes, and to ensure bioethics, safety, and improved public health and quality of life.

- (Human Subject Research) Research involving human participants through ① physical intervention, ② interaction such as communication and contact, and ③ use of personally identifiable information (Article 2,

Paragraph 1)

- (Human-Derived Material Research) Research directly analyzing human-derived materials (Article 2, Paragraph 12)

\* (Human-Derived Material) Tissue, cells, blood, body fluids, serum, plasma, chromosomes, DNA, RNA, proteins, etc. (Article 2, Paragraph 11)

○ **(Strengthening Role of IRB)** Mandatory review by IRB prior to conducting research involving human subjects or human-derived materials. Institutions are required to establish and operate an IRB. (Fines apply for violations.)

○ **(Shared IRB)** For individual researchers, small institutions, or SMEs that cannot establish their own IRB, shared IRBs designated by the Ministry of Health and Welfare may be used.

○ **(Scope of Research Requiring IRB Review)** Only studies involving human subjects or human-derived materials (including embryos, somatic cell clone embryos, parthenogenetic embryos, embryonic stem cell lines, etc.) fall under mandatory IRB review.

\* "Research" refers to systematic investigations including R&D, tests, and evaluations aimed at developing generalizable knowledge (per U.S. regulations such as HIPAA and 45 CFR 46).

- Simple surveys (exit polls, public opinion surveys) or business-related investigations (market research, customer satisfaction surveys) that do not aim to produce generalizable knowledge are not considered research under this law.

#### q **Compliance Requirements**

○ In accordance with the Bioethics and Safety Act, researchers conducting human subjects research or human-derived material research

must obtain review and approval from the IRB before signing the agreement for the applicable year.

○ Institutions conducting such research are required to establish and register an IRB.

- Institutions unable to establish their own IRB must arrange to use a designated public IRB through an agreement with the Ministry of Health and Welfare.

※ Contact Information for Related Inquiries

- For questions about the Bioethics and Safety Act, human subjects research, or human-derived materials research, please contact the following organization.
- Institutional Review Board of the National Institute for Bioethics Policy : <http://irb.or.kr>  
([irb@nibp.kr](mailto:irb@nibp.kr))

## Registration of R&D Information and Evaluation, Reporting, and Disclosure of R&D Results

### q Registration and Deposit of Research Outputs

○ To efficiently manage and promote shared use of research outputs by category, designated agencies are tasked with managing and distributing research outcomes.

※ Legal Basis: Notification on the Designation of Agencies for Research Outcome Management and Distribution (Notification No. 2020-107, enacted Jan. 1, 2021)

○ When a research output is generated, the researcher must confirm with the relevant department of the designated management/distribution agency in advance and proceed with registration or deposit of applicable outputs.

- However, for papers, patents, and full-text reports, researchers should register directly via the Integrated Research Support System ([www.iris.go.kr](http://www.iris.go.kr))

#### < Designated Research Outcome Management and Distribution Agencies >

Category	Research Output	Designated Agency	Scope (Registration/Deposit Criteria)
Registration	Academic Papers	KISTI ( <a href="https://rpms.kisti.re.kr">https://rpms.kisti.re.kr</a> )	Academic articles published in domestic/international journals or conference proceedings (including electronic full texts)
	Patents	Korea Patent Strategy Development Institute ( <a href="http://www.ripis.or.kr">http://www.ripis.or.kr</a> )	Patents filed or registered in Korea or abroad

Cat ego ry	Research Output		Designated Agency	Scope (Registration/Deposit Criteria)
	Full Reports		KISTI ( <a href="https://nrms.kisti.re.kr">https://nrms.kisti.re.kr</a> )	Full texts of annual, midterm, and final reports
	Research Facilities & Equipment		Korea Basic Science Institute ( <a href="http://nfec.ntis.go.kr">http://nfec.ntis.go.kr</a> )	Facilities/equipment acquired through national R&D programs worth ≥ KRW 30 million (incl. VAT), or suitable for shared use
	Technical Summary		KIAT ( <a href="https://www.ntb.kr">https://www.ntb.kr</a> )	Technical summaries of research outcomes from completed annual, midterm, and final reports
	Bio Resources	Bio Info	KRIBB ( <a href="http://biodata.kr">http://biodata.kr</a> / <a href="http://www.kobis.re.kr">http://www.kobis.re.kr</a> )	Genomic, proteomic, transcriptomic data, and related information
	Software		Korea Copyright Commission ( <a href="https://www.cros.or.kr">https://www.cros.or.kr</a> )	Created software and required metadata for registration
			NIPA ( <a href="https://www.swbank.kr">https://www.swbank.kr</a> )	
Standards		KSA ( <a href="http://www.rndstandard.or.kr">www.rndstandard.or.kr</a> )	Official standard information adopted as national standards under Article 3 of the Framework Act on National Standards or as international standards, including standard information adopted by officially recognized international standardization organizations (such as ISO, IEC, ITU) or de facto standardization organizations, including those involving relevant technical committees.	
		TTA ( <a href="http://rnd.tta.or.kr">rnd.tta.or.kr</a> )		
		KRISS (Measurement: <a href="http://eshop.kriss.re.kr">eshop.kriss.re.kr</a> ) (Reference: <a href="http://www.srd.re.kr">www.srd.re.kr</a> )		
Depo sit	Bio Resources	Bio Resources	KRIBB ( <a href="https://biorp.kribb.re.kr">https://biorp.kribb.re.kr</a> )	Microbiological resources (bacteria, fungi, viruses, etc.), animal resources (human or animal cells-fertilized eggs, etc.), plant resources (plant cells, seeds, etc.), genomic resources (DNA, RNA, plasmids, etc.), and other biological resources
	Compounds		Korea Research Institute of Chemical Technology ( <a href="http://www.chembank.org">http://www.chembank.org</a> )	Organic compounds (synthetic or natural) and related data
	New Varieties		National Academy of Agricultural Sciences ( <a href="http://genebank.rda.go.kr">http://genebank.rda.go.kr</a> )	Information on new agricultural varieties registered or filed domestically/abroad

\* KRIBB is the designated cross-ministerial bioresource center under Article 11 of the Bioethics Act, but physical specimens and information may also be deposited with organizations designated by relevant ministries under Article 8 of the same act.

#### q **Clinical Research Information Service (CRIS) Registration**

○ Scope: All types of clinical studies involving human subjects, including observational studies (e.g., cohort studies) and interventional studies (e.g., clinical trials).

○ To improve clinical research quality and share information, register applicable clinical studies in CRIS (<https://cris.nih.go.kr>), operated by the Korea NIH under KDCA.

※ CRIS inquiry: 043-249-3085

○ Include the CRIS registration number in performance reports.

- Clinical Research Information Service (CRIS) is an online registration system for clinical research, including clinical trials conducted in Korea, established and operated by the Korea National Institute of Health under the Korea Disease Control and Prevention Agency.
- In May 2010, CRIS was accepted as a Primary Registry by the WHO International Clinical Trials Registry Platform (ICTRP), enabling researchers to disclose their clinical research information not only domestically but also internationally, thereby fulfilling the registration requirements of international academic journals.

※ Notes for Registration

\* Timing: Ideally prior to first subject enrollment, but retrospective registration is allowed.

\* Authority: Requires CRIS user registration and approval for entry.

\* Info Maintenance: Update registration every 6 months until study completion.

#### q **CODA (Clinical & Omics Data Archive) Registration**

○ Subject: Applies to projects designated by the Ministry of Health and Welfare. A data management plan must be submitted with the research proposal.

- Research data refers to factual data essential for validating findings, obtained through experiments, surveys, or analyses.

- Data and metadata must be registered in accordance with the CODA system (<http://coda.nih.go.kr>) guidelines.

○ CODA is operated by KDCA's NIH to nationalize, share, and utilize research data from Ministry of Health and Welfare-funded projects.

CODA (Clinical & Omics Data Archive) system is an information system established by the Life Research Resource Information Center of the Ministry of Health and Welfare to promote the national resourceization, sharing, and utilization of research data generated from projects supported by the Ministry. It aims to strengthen domestic healthcare research capacity and enhance research productivity, and is built and operated by the Korea National Institute of Health under the Korea Disease Control and Prevention Agency.

※ Inquiry on registration and CODA system: NIH, KDCA - 043-249-3047

#### q **Registration and Disclosure of Published Papers**

○ To foster open innovation and R&D commercialization, research outcomes must be made publicly available.

※ Legal Basis: Article 5(7), National R&D Innovation Act

○ For papers resulting from Ministry of Health and Welfare R&D funding, submit the final electronic version to the National Medical Science Knowledge Center of KDCA within 12 months of journal publication.

- Researchers must retain copyright unless transferred. In such cases, notify the publisher of the obligation to submit the final version to the NIH.

※ Check publisher copyright policy at [library.nih.go.kr](http://library.nih.go.kr) → E-Resources Journal Information

※ Sample wording for use when signing a publication contract or copyright transfer agreement

(출판사명 또는 학회명)은 저자가 게재 확정된 최종 원고를 국립보건연구원에 제출함으로써, 논문의 공식 출판 12개월 이내에 국립보건연구원이 운영하는 디지털 보존소를 통해 일반에 공개할 수 있는 권리를 보유한다는 점을 인지하고 있다.

((Journal) acknowledges that Author retains the right to provide a copy of the final manuscript to the Korea National Institute of Health (KNIH) upon acceptance for Journal publication, for public archiving in KNIH-operating digital repository as soon as possible but no later than 12 months after publication by (Journal))

※ Inquiry: National Medical Science Knowledge Center, KDCA - 043-249-3000 /  
ncmik@korea.kr

#### q Criteria for Awarding or Deducting Points

○ In accordance with Article 12, Paragraphs 4 and 5 of the Enforcement Decree of the National Research and Development Innovation Act, preferential or disadvantageous treatment may be applied based on the criteria that specify eligible R&D institutions.

※ Point adjustments are based on the project application deadline.

※ Points are applied during the final scoring stage.

※ When multiple bonus categories (final evaluation bonus, research achievement award bonus, healthcare technology contributor bonus) apply to the same achievement, only one bonus may be granted.

※ If the bonus for “Innovative Pharmaceutical/Medical Device Company” is applied, the bonus for “Outstanding In-house Research Institute” cannot be applied concurrently.

Item	Score	Applicable To	Remarks
Bonus for Research Performance Awards	0.3	<p>If the research director has received a national honor within the past three years in accordance with Article 17(4) of the Enforcement Decree of the National R&amp;D Innovation Act and is applying for a new R&amp;D project.</p> <p>- Limited to Orders, Medals, or Presidential Citations</p> <p>* Only applicable once. If the research director applies for multiple projects, the bonus may only be claimed for one project.</p>	<p>Refer to Standard Guidelines for Evaluation of National R&amp;D Projects</p>

Item	Score	Applicable To	Remarks
<p>Bonus for Selection in “Top 100 Excellent R&amp;D Achievements”</p>	<p>0.3</p>	<p>If the research director was selected for the “Top 100 Excellent R&amp;D Achievements” within the past three years and is applying for a new R&amp;D project. * Only applicable once. If the research director applies for multiple projects, the bonus may only be claimed for one project.</p>	<p>Refer to Standard Guidelines for Evaluation of National R&amp;D Projects</p>
<p>Penalty for Project Abandonment or Discontinuation</p>	<p>-3</p>	<p>If the researcher or R&amp;D institution was sanctioned for abandoning a project without justifiable cause and is applying for a new R&amp;D project. * Valid for three years from the end date of the participation restriction.</p>	<p>Article 12(5) and Appendix 6 of the</p>
<p>Penalty for Research Misconduct</p>	<p>-5</p>	<p>If the researcher or R&amp;D institution was sanctioned for research misconduct and is applying for a new R&amp;D project. * Valid for three years from the end date of the participation restriction.</p>	<p>Enforcement Decree of the Innovation Act</p>